Valeo Pharma
  • About Us
    • Overview
    • Board of Directors
    • Management Team
  • Product Portfolio
    • Respiratory
    • Specialty Products
    • Neurology
    • Oncology
  • Partnering
  • Investors
    • Investor Relations
    • Stock information
    • Corporate Presentation
    • Financial Reports
    • Newsroom
    • Webcasts / Events
    • SEDAR documents
  • Careers
  • Contact
  • Français
  • Corporate Presentation
Select Page
VALEO PHARMA TO HOST FIRST QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST AND ATTEND THE 8TH ANNUAL ALPHANORTH CAPITAL CONFERENCE    

VALEO PHARMA TO HOST FIRST QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST AND ATTEND THE 8TH ANNUAL ALPHANORTH CAPITAL CONFERENCE    

by Fred Dumais | Mar 17, 2022 | News Release

MONTREAL, QUEBEC , March 17, 2022 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2022...
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL 2021 

VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL 2021 

by Fred Dumais | Mar 1, 2022 | News Release

Record  revenues in 2021 of $13.6 million, up 81% over 2020 Annual Gross Margins for 2021, $4 Million, up 186% over 2020Q4-21 revenues of $3.4 million, up 53% over Q4-20Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®, three transformational...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR  ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK

VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR  ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK

by Fred Dumais | Feb 24, 2022 | News Release

Atectura and Enerzair also now reimbursed by the Non-Insured Health Benefits (“NIHB”) program of Indigenous Services Canada and Veteran Affairs Canada (“VAC”)Public reimbursement now includes Ontario, Quebec, Alberta, Manitoba, Nova Scotia, New Brunswick, NIHB and VAC...
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL 2021 

VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2021 RESULTS CONFERENCE CALL / WEBCAST  

by Fred Dumais | Feb 21, 2022 | News Release

MONTREAL, QUEBEC , February 21, 2022 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended...
VALEO PHARMA’S HESPERCO™ NOW AVAILABLE AT LOBLAWS,  HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION

VALEO PHARMA’S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION

by Fred Dumais | Jan 5, 2022 | News Release

Hesperco now available in approximately 300 stores under the Loblaws bannersClinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms MONTREAL, QUEBEC , January 5, 2022 – Valeo Pharma Inc. (CSE:VPH, OTCQB:VPHIF, FSE:VP2)...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR  ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA

VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA

by Fred Dumais | Dec 15, 2021 | News Release

Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population.More than 90% private insurance coverage across Canada MONTREAL, QUEBEC , December 15, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE:...
« Older Entries
Next Entries »

Recent News

  • VALEO PHARMA ANNONCE LES RÉSULTATS DE L’ASSEMBLÉE ANNUELLE DES ACTIONNAIRES, LES NOMINATIONS ET LES ATTRIBUTIONS D’OPTIONS ET D’UNITÉS D’ACTIONS RESTREINTES April 28, 2022
  • VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS, APPOINTMENTS AND OPTIONS AND RSU GRANTS April 28, 2022
  • VALEO PHARMA PRÉSENTERA À LA CONFÉRENCE POUR INVESTISSEURS SUR LA SANTÉ 2022 DE BLOOM BURTON & CO   April 25, 2022
  • VALEO PHARMA TO PRESENT AT THE 2022 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE   April 25, 2022

Stay in the loop

I consent to receive news, updates and special offers from Valeo Pharma and it’s affiliates.

Contact us

1-855-694-0151
info@valeopharma.com
16667 Hymus Blvd.
Kirkland, QC H9H 4H9
  • About Us
  • Board of Directors
  • Management Team
  • Careers
  • Our Products
  • Business Development
  • Investors Overview
  • Newsroom
  • Stock Information
  • Financial Reports
  • Contact Us
  • Français

© 2022 Valeo Pharma. All rights reserved.

Speak to a professional

I want to speak to:

9 + 9 =